Merlin Entertainments PLC (LON:MERL) Was Upgraded by Berenberg; 683 Capital Management Has Decreased Alnylam Pharmaceuticals (ALNY) Position By $3.57 Million

March 2, 2018 - By rebbecca

Equity analysts at Berenberg’s equities research division upgraded Merlin Entertainments PLC (LON:MERL)‘s stock to “Hold” on 2 March. The professional analysts at Berenberg have a target price per share of GBX 360.00 on MERL or 1.81% more upside.

683 Capital Management Llc decreased Alnylam Pharmaceuticals Inc (ALNY) stake by 11.3% reported in 2017Q3 SEC filing. 683 Capital Management Llc sold 30,500 shares as Alnylam Pharmaceuticals Inc (ALNY)’s stock rose 48.45%. The 683 Capital Management Llc holds 239,500 shares with $28.14M value, down from 270,000 last quarter. Alnylam Pharmaceuticals Inc now has $11.88B valuation. The stock decreased 0.86% or $1.03 during the last trading session, reaching $119.13. About 620,193 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since March 2, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Among 19 analysts covering Merlin Entertainments PLC (LON:MERL), 14 have Buy rating, 0 Sell and 5 Hold. Therefore 74% are positive. Merlin Entertainments PLC has GBX 600 highest and GBX 360 lowest target. GBX 452.28’s average target is 22.24% above currents GBX 370 stock price. Merlin Entertainments PLC had 184 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, February 19 by Deutsche Bank. The firm has “Overweight” rating given on Thursday, December 21 by Barclays Capital. The rating was maintained by Barclays Capital on Thursday, January 12 with “Overweight”. Citigroup maintained it with “Buy” rating and GBX 475 target in Monday, September 7 report. Panmure Gordon maintained Merlin Entertainments plc (LON:MERL) on Thursday, February 25 with “Buy” rating. On Friday, July 31 the stock rating was maintained by Beaufort Securities with “Buy”. JP Morgan upgraded the stock to “Neutral” rating in Wednesday, June 29 report. On Thursday, October 22 the stock rating was maintained by Beaufort Securities with “Buy”. The stock of Merlin Entertainments plc (LON:MERL) earned “Buy” rating by Beaufort Securities on Friday, February 26. Deutsche Bank maintained Merlin Entertainments plc (LON:MERL) on Wednesday, January 3 with “Buy” rating.

Merlin Entertainments plc operates visitor attraction places worldwide. The company has market cap of 3.77 billion GBP. The firm operates midway attractions under the Madame Tussauds, The Eye Brand, SEA LIFE, The Dungeons, LEGOLAND Discovery Centres, Seal Sanctuaries, Blackpool Tower, WILD LIFE, Australian Treetop Adventures, Hotham Alpine Resort, Falls Creek, and Shreks Adventure London brands. It has a 17.87 P/E ratio. It also operates LEGOLAND parks under the LEGOLAND Billund, LEGOLAND Windsor, LEGOLAND California, LEGOLAND Deutschland, LEGOLAND Florida, LEGOLAND Malaysia, LEGOLAND Dubai, and LEGOLAND Japan brands; and resort theme parks under the Alton Towers, Chessington World of Adventures, Gardaland, Heide Park, THORPE PARK Resort, and Warwick Castle brand names.

The stock decreased 0.54% or GBX 2 during the last trading session, reaching GBX 370. About 664,873 shares traded. Merlin Entertainments plc (LON:MERL) has 0.00% since March 2, 2017 and is . It has underperformed by 16.70% the S&P500.

Since September 20, 2017, it had 0 insider purchases, and 3 sales for $23.18 million activity. Shares for $7.68 million were sold by Greene Barry E. Shares for $4.84M were sold by Mason Michael.

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals has $220 highest and $34 lowest target. $123.81’s average target is 3.93% above currents $119.13 stock price. Alnylam Pharmaceuticals had 97 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Chardan Capital Markets on Thursday, October 6 with “Buy”. Jefferies initiated it with “Buy” rating and $107 target in Friday, October 23 report. The firm has “Neutral” rating given on Thursday, September 29 by Janney Capital. On Wednesday, November 8 the stock rating was maintained by BMO Capital Markets with “Buy”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Sell” rating by Nomura on Friday, September 15. Leerink Swann maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, January 25 with “Market Perform” rating. B. Riley & Co maintained it with “Buy” rating and $220 target in Wednesday, November 8 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Jefferies on Friday, February 9. Piper Jaffray maintained the stock with “Buy” rating in Friday, December 15 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Bernstein on Thursday, September 21.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on May, 4. They expect $-1.52 EPS, down 21.60% or $0.27 from last year’s $-1.25 per share. After $-1.48 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 2.70% negative EPS growth.